Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has mat...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :CPT Pharmacometrics Syst Pharmacol
Главные авторы: Stroh, M, Carlile, DJ, Li, C-C, Wagg, J, Ribba, B, Ramanujan, S, Jin, J, Xu, J, Charoin, J-E, Xhu, Z-X, Morcos, PN, Davis, JD, Phipps, A
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Ltd 2015
Предметы:
Perspective
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4592528/
https://ncbi.nlm.nih.gov/pubmed/26451328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12014
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы